Maryland Oncology Hematology

What Maryland Oncology Hematology does

Maryland Oncology Hematology (MOH) is a private, physician-owned community oncology and hematology practice operating from 18 office locations across Maryland and Washington D.C. The practice delivers integrated cancer and blood-disorder care through medical oncology, hematology, surgical oncology (breast, colorectal, gynecologic), radiation oncology (including a Varian TrueBeam linear accelerator at Silver Spring), in-house CLIA-certified laboratory services, and clinical trials run in partnership with the Sarah Cannon Research Institute (58 active trials at last reporting). MOH launched an in-house Next Generation Sequencing laboratory in April 2026 to enable faster genomic testing for precision medicine and trial enrollment.

The practice services a primarily B2C customer base — cancer and hematology patients, second-opinion seekers, and chronic-disease patients receiving multi-specialty infusion therapy. MOH functions as a member of The US Oncology Network, which provides shared research, operational, and best-practice infrastructure while the practice retains physician-led governance. Ancillary revenue lines include a Medically Integrated Dispensary for oral oncology medications, a Paxman Scalp Cooling System, financial counseling, social work, nurse navigation, telehealth consultations, and a patient portal.

MOH generates revenue predominantly through patient care services billed to insurance payors (Medicare, Medicaid, commercial). Its GTM motion combines sales-led referral relationships with primary care and specialist physicians, self-referrals and second-opinion consults, and a community-led hook via access to cutting-edge Sarah Cannon trials. Customer acquisition is largely physician-referral driven across its 18-site footprint; no direct-to-patient paid acquisition channel was identified.

Name

Maryland Oncology Hematology

Legal name

Maryland Oncology Hematology

Website

https://marylandoncology.com

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Maryland Oncology Hematology is a physician-owned community oncology and hematology practice operating 18 locations across Maryland and Washington D.C., delivering integrated cancer care, clinical trials, radiation oncology, in-house NGS diagnostics, and infusion therapy.

Ownership category

akta.pro rank

Product category

Oncology and Hematology Care Services

NAICS

Offices of Physicians (62111), Offices of Physicians (except Mental Health Specialists) (621111), Medical Laboratories (621511)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000), Services-Medical Laboratories (8071)

akta.pro primary industry

Medical Oncology (HLAKAFAB)

akta.pro secondary industries

Surgical Oncology (HLAKAFAG), Breast Oncology (HLAKAFAJ), Gynecologic Oncology (HLAKAFAF)

Keywords

• Oncology hematology services
• Cancer treatment services
• Clinical trials oncology
• Radiation oncology
• Hematology diagnostics

Headquarters

HQ city

Columbia

HQ country

United States

HQ region

North America

Offices9 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Patient Care Services: Revenue generated from providing integrated cancer care and hematology services including chemotherapy, radiation oncology, laboratory testing, and clinical trials. Services are billed to insurance providers including Medicare and Medicaid.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Maryland Oncology Hematology delivers integrated, evidence-based cancer care and hematology services across 18 locations in Maryland and Washington D.C. The practice provides chemotherapy, radiation oncology (including Varian TrueBeam), surgical oncology, targeted therapy and precision medicine, hematology, in-house laboratory services, and a Medically Integrated Dispensary. It also runs clinical trials through a partnership with the Sarah Cannon Research Institute and recently launched an in-house Next Generation Sequencing laboratory for genomic testing.

Product overview

Maryland Oncology Hematology operates as an integrated oncology and hematology practice offering a comprehensive suite of cancer care and clinical research services across Maryland and Washington, D.C. The organization functions as a unified healthcare delivery platform rather than a modular product architecture, providing chemotherapy, radiation oncology (including Varian™ TrueBeam™ Linear Accelerator), surgical services (breast, colorectal, gynecologic oncology), targeted therapy with precision medicine, hematology, laboratory services, and a medically integrated dispensary. The practice recently launched an in-house Next Generation Sequencing (NGS) laboratory for rapid cancer genetic analysis. Additional services include the Paxman Scalp Cooling System for hair loss prevention, genetic risk assessment, financial counseling, social work support, telehealth consultations, and a patient portal. Through partnership with the Sarah Cannon Research Institute, the practice offers access to numerous clinical trials spanning multiple cancer types.

Differentiator

Problem solved

Functional benefit

Products and services

• Chemotherapy

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and major.

• Sarah Cannon Research InstitutecoreStrategic or Co-development PartnerClinical trial partnership providing access to leading-edge cancer clinical trials for a wide range of cancers and blood disorders. This partnership gives patients access to the next generation of therapies through ongoing research studies.
• The US Oncology NetworkcoreStrategic or Co-development PartnerMaryland Oncology Hematology is a member of The US Oncology Network, the largest independent oncology practice in Maryland. This network provides access to shared best practices, research collaborations, and clinical resources.
• Aquilino Cancer CentermajorStrategic or Co-development PartnerPartnership for the Rockville location at 9905 Medical Center Drive. The center features world-class research facilities and houses specialized surgeons. Located on the Shady Grove Medical Center campus.
• White Oak Cancer CentermajorStrategic or Co-development PartnerSilver Spring location partnership providing comprehensive cancer care including medical oncology, radiation oncology with Varian TrueBeam technology, and breast/gynecological surgery services.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Texas Oncology: Texas Oncology is the largest community-based oncology practice in the U.S. and a fellow member of The US Oncology Network. It is directly comparable to MOH in multi-specialty community oncology delivery, physician-owned governance, and USON-affiliated research participation, just at substantially greater scale.
• Virginia Cancer Specialists: Virginia Cancer Specialists is a large community oncology and hematology practice in Northern Virginia, sharing the same mid-Atlantic regional footprint, multi-specialty delivery model (medical oncology, hematology, radiation, infusion, clinical trials), and physician-led structure as MOH.
• Compass Oncology: Compass Oncology is a Pacific Northwest community oncology group and member of The US Oncology Network. It mirrors MOH's integrated medical oncology, radiation oncology, and clinical trial delivery model through USON, with similar physician-owned governance and multi-site operations.
• Tennessee Oncology: Tennessee Oncology is one of the largest independent community oncology practices in the U.S. with comprehensive medical oncology, hematology, radiation, and clinical research services across multiple sites. Its scale, services, and Sarah Cannon-affiliated research strongly mirror MOH's operating model.
• Oncology Hematology Care: Oncology Hematology Care (OHC) is a Cincinnati-based community oncology practice affiliated with US Oncology Network. It offers the same integrated medical oncology, hematology, infusion, and clinical trial services as MOH in a community setting, with comparable physician-ownership and USON membership.
• New York Oncology Hematology: New York Oncology Hematology (NYOH) is a large community oncology and hematology practice in the Albany, NY region and a US Oncology Network affiliate. Its multi-site community oncology delivery model, hematology focus, and research portfolio closely parallel MOH's structure.
• Northwest Medical Specialties: Northwest Medical Specialties is a community-based oncology and hematology practice in the Pacific Northwest offering multi-specialty cancer care, infusion, and clinical trials. It is comparable to MOH as an independent, multi-site community oncology provider of similar scale.

Broad incumbents

• Johns Hopkins Sidney Kimmel Cancer Center: Johns Hopkins Sidney Kimmel Cancer Center is the dominant academic cancer program in Maryland, the same primary geography as MOH. While not community-based, it competes for complex oncology cases and serves as a research benchmark that MOH positions its clinical trial portfolio against.
• University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center: University of Maryland Greenebaum Cancer Center is a Baltimore-based academic cancer center providing medical oncology, radiation, surgical oncology, and clinical trials in MOH's primary market. It is a broad incumbent competitor for referrals and specialty oncology cases.

Others

• Sarah Cannon Research Institute: Sarah Cannon Research Institute is MOH's strategic clinical trial partner and a major oncology research organization affiliated with HCA Healthcare. While not a direct competitor, it is an ecosystem participant that enables MOH's clinical trial portfolio and is materially comparable as a research delivery platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key highlights7 records

Customer concentration

• Xx.com/MDCancercare
• Facebookfacebook.com/MarylandOncologyHematology

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maryland Oncology Hematology